TrialBlood advances2026

Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R marginal zone lymphoma: phase 1/2 BRUIN study.

Krish Patel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.